Ignite Creation Date:
2025-12-24 @ 12:37 PM
Ignite Modification Date:
2026-02-26 @ 6:53 AM
Study NCT ID:
NCT03728361
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-18
First Post:
2018-10-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Sponsor:
Dwight Owen
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Grade I Neuroendocrine Carcinoma | View |
| None | Grade II Neuroendocrine Carcinoma | View |
| None | Grade III Neuroendocrine Carcinoma | View |
| None | Metastatic Neuroendocrine Carcinoma | View |
| None | Neuroendocrine Carcinoma | View |
| None | Recurrent Small Cell Lung Carcinoma | View |
| None | Refractory Small Cell Lung Carcinoma | View |
| None | Lung Cancer Stage IV | View |
| None | Large Cell Neuroendocrine Carcinoma | View |
| None | Neuroendocrine Tumors | View |
| None | Small Cell Lung Cancer Metastatic | View |
| None | Small-cell Lung Cancer | View |
Keywords: